You don't need to be Socrates to see that holding this is a losing proposition.
When you think about the following, just how little is destined to trickle to ACR, makes a lot of sense:
Divide by 2 to account for rebates & chargebacks demanded by the end-customer (paid for by the pharma co.).
Divide by 2 again, to account for sales-costs.
Divide by 2 again, to account for partner's share.
Divide by 5 to account for competitors.
And then consider that ACR's partners are small compared to competitors (Teva, Viatris, Sandoz, Amneal, Dr Reddys, Aurobindo, Endo etc) who will get the lion's share.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
